Insider Buying: PureTech Health (LON:PRTC) Insider Purchases 50,000 Shares of Stock

PureTech Health plc (LON:PRTC) insider John LaMattina bought 50,000 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was bought at an average price of GBX 119 per share, for a total transaction of £59,500.

PureTech Health Trading Up 1.6%

Shares of PRTC stock opened at GBX 120 on Thursday. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The firm has a market cap of £292.10 million, a P/E ratio of -2.61 and a beta of 0.79. The company has a 50 day moving average of GBX 129.88 and a 200-day moving average of GBX 127.13. PureTech Health plc has a 12-month low of GBX 104.71 and a 12-month high of GBX 148.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.